Pharma's 340B Legal Disputes Over Contract Pharmacies May Get A Boost With Chevron Ruling

 
• By Cathy Kelly

But the overall impact of the Supreme Court decision may not seem as “immediate” in 340B compared to other federal programs.

Rebalancing The Power Between Executive Agencies And The Judiciary • Source: Shutterstock (Shutterstock)

The Supreme Court’s recent decision to overturn the Chevron doctrine, which means lower courts may no longer defer to federal agencies’ “reasonable” interpretations of ambiguous statutes, could help manufacturers prevail in ongoing lawsuits challenging the participation of contract pharmacies in the 340B drug discount program.

Key Takeaways

  • Supreme Court ruling overturning the Chevron doctrine could help manufacturers prevail in 340B contract pharmacy litigation against the Health Resources and Services Administration.

The decision is also expected to support litigation challenging a range of regulatory actions by the US Food and Drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

BIO Notebook: MFN Pricing, Obesity R&D, US FDA’s Rare Disease Hub And Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 
• By Francesca Bruce

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.

Pink Sheet Podcast: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

 
• By Derrick Gingery, Francesca Bruce, Cathy Kelly, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.

More from Market Access